BTIG on Moonlake Immunotherapeutics (MLTX): 'An Underappreciated and Large Market Opportunity in Rheumatology'
Tweet Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $24.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst comments "Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
